Collectively, these in vivo findings confirm that R-irisin mitigates Dex-induced muscle atrophy and mitochondrial dysfunction through SIRT1-dependent pathways, reinforcing its therapeutic potential for sarcopenic disorders. Here, SIRT1 is linked to muscle atrophy.